[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"solid-tumor-metastatic-cancer-advanced-cancer\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:solid-tumor-metastatic-cancer-advanced-cancer":25},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":29,"startDateStruct":32,"completionDateStruct":34,"leadSponsor":36,"locationsCount":5},"100610980","role-of-fibrinolytic-activity-in-neoplastic-pathologies-complicated-by-coagulopathy-100610980",false,"NCT07234630","Role of Fibrinolytic Activity in Neoplastic Pathologies Complicated by Coagulopathy","NEO-COAG","Inclusion Criteria:\n\nFor all groups:\n\n* Age \\> 18 years\n* Patient hospitalized in Emergency Medicine, Intensive Care Medicine or Hematology\u002FOncology Intensive Care, Hematology\u002FOncology Service or Hepatobiliary and Digestive Surgery Service\n* Coagulopathy defined by the combination of thrombocytopenia (\\\u003C 100 G\u002FL) and increased INR (\\>1.2)\n\nGroup 1: Malignant hemopathies with large tumor masses:\n\n* Acute myeloblastic or lymphoblastic leukemia with leukocyte count (or blasts) \\>50G\u002FL in peripheral blood, or\n* Lymphoma documented by tissue biopsy, with biological tumor lysis syndrome, diagnosed according to Cairo and Bishop criteria (3).\n\nGroup 2: Locally advanced or metastatic solid tumors with DIC:\n\n* Prostatic adenocarcinoma\n* Malignant pancreatic or biliary tract tumor (cholangiocarcinoma),\n* Scheduled complex hepatobiliary carcinological surgery,\n* Metastatic adenocarcinoma of the digestive tract.\n\nGroup 3: Control group (free of neoplastic pathology, with well-studied coagulopathy): Septic shock\n\nExclusion Criteria:\n\n* Patient under protective supervision (guardianship or curatorship)\n* Pregnant women\n* Patients weighing less than 50 kg\n* Patient already included in the study\n* Congenital hemostasis disorders\n* Active bleeding at the time of inclusion\n* Patient with cirrhosis\n* Patients receiving curative anticoagulation therapy\n* Patients with a spontaneous INR \\> 1.2 in a previous blood test in a context of fibrinolytic insufficiency\n* Each group is exclusive of the other, for example :\n\nFor Group 1 (Neoplastic pathologies): Presence of documented sepsis at the time of inclusion","ALL","18 Years",{"count":19,"type":20},150,"ESTIMATED","OBSERVATIONAL","The aim of this research is to measure fibrinolytic activity in neoplastic pathologies in order to provide preliminary data on which to base a future, larger-scale study to determine predictive markers of complication in order to improve patient management.\n\nPrimary purpose: measure plasminogen concentration on day 1 in subjects diagnosed with malignant hematological disease, solid tumors, or septic shock, with coagulopathy.\n\nSecondary purpose:\n\n* Estimate the difference in plasminogen concentration at D1 in patients with coagulopathy between subjects with a diagnosis of haematological malignancy and those with solid tumor\n* Estimate the difference in plasminogen concentration at D1 in patients with coagulopathy between subjects with a diagnosis of haematological malignancy and those with septic shock\n* Estimate the difference in plasminogen concentration on Day 1 in patients with coagulopathy between subjects with a diagnosis of solid tumor and those with septic shock.\n\nIn the 3 groups, subjects with a diagnosis of haematological malignancy, solid tumor, septic shock, presenting with coagulopathy:\n\n* Evaluate the correlation between the concentration of circulating plasminogen active on Day 1 and the occurrence of a bleeding complication within 28 days of admission to critical care.\n* Evaluate the correlation between the concentration of circulating plasminogen active on Day 1 and the occurrence of a thrombotic complication, within 28 days of admission to critical care.\n* Evaluate the predictive performance of circulating active plasminogen concentration on Day 1 in the need for extra renal purification within 28 days of admission to critical care.\n* Estimate the differences at each time point (D1, D3, D7) in haemostasis markers and markers of fibrinolytic activity and its regulation.\n\nAssess the link between fibrinolytic activity and :\n\n* The diagnosis of disseminated intravascular coagulation (DIC),\n* The risk of haemorrhage\n* Risk of organ failures\n* Thrombotic risk\n* Risk of organ failure\n* Neutrophile activation and circulating NETs levels",[24,25,26],"Hematologic Neoplasms","Solid Tumor Metastatic Cancer Advanced Cancer","Disseminated Intravascular Coagulation","NOT_YET_RECRUITING","2025-12-09",{"date":30,"type":31},"2025-12-10","ACTUAL",{"date":33,"type":20},"2026-01",{"date":35,"type":20},"2028-02",{"name":37,"class":38},"University Hospital, Strasbourg, France","OTHER"]